Assuntos
Arginina/uso terapêutico , Heme/uso terapêutico , Porfiria Aguda Intermitente/tratamento farmacológico , Complicações na Gravidez , Adulto , Feminino , Seguimentos , Humanos , Recém-Nascido , Masculino , Porfobilinogênio/metabolismo , Porfiria Aguda Intermitente/metabolismo , Porfirinas/sangue , Gravidez , Resultado da Gravidez , Fatores de RiscoRESUMO
AIM: To evaluate efficiency of estrogen-gestagen treatment for protection of the ovaries during polychemotherapy. MATERIALS AND METHODS: Ultrasonography of the pelvic organs, radioimmunoassay of LH, FSH, prolactin, E2, testosterone were performed in 95 women of child-bearing age with different stages of Hodgkin's disease. RESULTS: Cytostatic therapy of Hodgkin's disease had ovariotoxic effects and led to amenorrhea in 83% of the examinees. Regular estrogen-gestagen treatment protected ovaries in 86% of the patients. CONCLUSION: It is recommended for women to take estrogen-gestagen drugs to protect ovaries during polychemotherapy of Hodgkin's disease.
Assuntos
Amenorreia/prevenção & controle , Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Estrogênios/uso terapêutico , Doença de Hodgkin/tratamento farmacológico , Ovário/efeitos dos fármacos , Progestinas/uso terapêutico , Reprodução , Adolescente , Adulto , Amenorreia/sangue , Amenorreia/induzido quimicamente , Quimioterapia Combinada , Estradiol/sangue , Feminino , Gonadotropinas Hipofisárias/sangue , Doença de Hodgkin/sangue , Doença de Hodgkin/diagnóstico , Humanos , Pessoa de Meia-Idade , Ovário/diagnóstico por imagem , Pelve/diagnóstico por imagem , Radioimunoensaio , Reprodução/efeitos dos fármacos , Testosterona/sangue , UltrassonografiaRESUMO
AIM: To evaluate the effect of estrogen gestagenic drugs (EGD) on blood coagulation in patients with blood malignancies treated by polychemotherapy. MATERIALS AND METHODS: 32 females of reproductive age treated with ovarioprotector marvelon during cytostatic therapy. The following indices were determined: activated partial thrombin time, prothrombin index of the ethanol test, fibrinogen and antithrombin III levels, factor XIIa dependent time of fibrinolysis, thrombin time. Dopplerography of the lower limb vessels was carried out. RESULTS: No significant alterations in coagulograms of the patients treated with cytostatics in combination with EGD were recorded. CONCLUSION: It is safe to use EGD as ovarioprotectors in females with hematological malignancies in hypercoagulation.
Assuntos
Protocolos de Quimioterapia Combinada Antineoplásica/efeitos adversos , Coagulação Sanguínea , Congêneres do Estradiol/uso terapêutico , Neoplasias Hematológicas/sangue , Congêneres da Progesterona/uso terapêutico , Adolescente , Adulto , Coagulação Sanguínea/efeitos dos fármacos , Fatores de Coagulação Sanguínea/metabolismo , Quimioterapia Combinada , Feminino , Seguimentos , Neoplasias Hematológicas/tratamento farmacológico , Humanos , Reprodução/efeitos dos fármacos , Resultado do TratamentoRESUMO
A menstrual function was studied in 24 females treated by drugs for advanced stages of Hodgkin's disease. 17 of them received oral contraceptives for preventing gonadotoxic effect of cytostatic agents (the study group). 7 women did not use contraceptives (the control group). After chemotherapy menstrual cycle was normal in 88.2% of patients of the study group, whereas in 71.4% of controls artificial menopause developed. Oral contraceptives can be recommended to protect the ovaries in the course of chemotherapy.
